On April, 29 Biofrontera AG (NASDAQ:BFRA)’s earnings report is anticipated by WallStreet, RTT reports. Analysts have expectation on stock’s earnings per share of $-0.08. That’s up 11.11 % from last year’s $-0.09 earnings per share. Analysts at Wall Street see Biofrontera AG’s -65.22 % EPS growth compared to $-0.23 earnings per share for last quarter. Lastly it traded at $12.96.It’s since March 29, 2018 and is 0.00% down. The stock underperformed the S&P 500 by 4.37%.

Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatologically tested cosmetics for the treatment and care of diseased skin.The firm is worth $292.03 million. The Company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, atopic dermatitis, or psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp's natural balance; Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities; belixos To Go for relief from itchiness, insect bites, and minor burns; and Belixos PROTECT for the needs of sun-damaged skin.Last it reported negative earnings. The firm is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis.

For more Biofrontera AG (NASDAQ:BFRA) news released recently go to: Globenewswire.com, Globenewswire.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Ruling by the U.S. District Court of Massachussetts – GlobeNewswire” released on December 27, 2018, “Biofrontera receives FDA approval for upscaling of batch size for Ameluz® production – GlobeNewswire” on January 08, 2019, “Changes in the composition of the Supervisory Board – GlobeNewswire” with a publish date: March 27, 2019, “Biofrontera AG (BFRA) CEO Hermann Lübbert on Q3 2018 Results – Earnings Call Transcript – Seeking Alpha” and the last “Biofrontera AG (Nasdaq: BFRA) to Ring The Nasdaq Stock Market Closing Bell – GlobeNewswire” with publication date: February 14, 2018.